May 14, 2020 / 1:14 PM / 19 days ago

BRIEF-Zealand Pharma Q1 Operating Loss Widens To DKK 177.2 Mln

May 14 (Reuters) - Zealand Pharma A/S:

* ZEALAND PHARMA FILES NEW DRUG APPLICATION WITH U.S. FDA FOR DASIGLUCAGON HYPOPAL® RESCUE PEN, SECURES DKK 137 MILLION IN ADDITIONAL INVESTMENT, AND ACCELERATES READINESS OF U.S. COMMERCIAL OPERATIONS: INTERIM REPORT FOR Q1 2020

* ZEALAND PHARMA FILES NEW DRUG APPLICATION WITH U.S. FDA FOR DASIGLUCAGON HYPOPAL® RESCUE PEN, SECURES DKK 137 MILLION IN ADDITIONAL INVESTMENT, AND ACCELERATES READINESS OF U.S. COMMERCIAL OPERATIONS: INTERIM REPORT FOR Q1 2020

* Q1 OPERATING LOSS DKK 177.2 MILLION VERSUS LOSS DKK 135.8 MILLION YEAR AGO

* Q1 REVENUE DKK 12.4 MILLION VERSUS DKK 0.0 MILLION YEAR AGO

* OPERATING EXPENSES IN 2020 ARE EXPECTED TO BE WITHIN RANGE OF DKK 950-1,000 MILLION Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below